Ascentage Pharma Group International (06855) has announced that on September 17, 2026, its appointed trustee purchased a total of 50,000 existing shares on the market to fulfill obligations under the 2022 Restricted Share Unit Scheme upon vesting.

This on-market acquisition was carried out specifically for the purpose of the RSU plan, ensuring that the company can satisfy the delivery of shares to eligible participants once the restricted share units vest according to the scheme's terms.

The purchase reflects the company's continued commitment to aligning employee incentives with long-term shareholder value, as the shares will be held by the trustee until they are allocated to plan participants in accordance with the vesting schedule.

No further details regarding the exact purchase price or the identity of the seller were disclosed in the official filing, which simply confirmed the transaction's occurrence and its alignment with the scheme's stated objectives.

This move is part of standard corporate governance practices, where companies often pre-purchase shares to ensure adequate supply for equity incentive programs, thereby avoiding potential dilution issues or market disruptions at the time of vesting.